Status:
ACTIVE_NOT_RECRUITING
Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma
Lead Sponsor:
Waikato Hospital
Collaborating Sponsors:
Wellington Hospital
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Glioblastoma (GBM), a very aggressive brain tumour, is one of the most malignant of all cancers and is associated with a poor prognosis. The majority of GBM cells display damaged mitochondria (the "ba...
Detailed Description
Gliomas are tumours that originate from glial cells in the central nervous system. The most common histological subtype is GBM, which accounts for nearly 50% of all malignant brain tumours. Despite ag...
Eligibility Criteria
Inclusion
- Age 18 years or greater.
- Newly-diagnosed histologically-confirmed GBM.
- ECOG Performance Status 0-2.
- Planned for 6 weeks of standard chemoradiation for GBM.
- If receiving dexamethasone, the dose must be ≤ 4 mg daily (and not increasing) upon commencement of the MTP.
Exclusion
- Ineligible for standard treatment for GBM due to poor performance status, co-morbidities, or inability to give informed consent.
- Type 1 diabetes.
- A medical or psychiatric disorder that, in the opinion of the investigators, would make it unlikely that the patient could adhere to the MTP.
Key Trial Info
Start Date :
May 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 26 2026
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04730869
Start Date
May 26 2021
End Date
June 26 2026
Last Update
June 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Waikato Hospital
Hamilton, Waikato Region, New Zealand, 3204